HRP20250471T1 - Glodavci koji eksprimiraju egzogenu terminalnu dezoksinukleotidil transferazu - Google Patents

Glodavci koji eksprimiraju egzogenu terminalnu dezoksinukleotidil transferazu Download PDF

Info

Publication number
HRP20250471T1
HRP20250471T1 HRP20250471TT HRP20250471T HRP20250471T1 HR P20250471 T1 HRP20250471 T1 HR P20250471T1 HR P20250471T T HRP20250471T T HR P20250471TT HR P20250471 T HRP20250471 T HR P20250471T HR P20250471 T1 HRP20250471 T1 HR P20250471T1
Authority
HR
Croatia
Prior art keywords
immunoglobulin
human
light chain
variable region
constant region
Prior art date
Application number
HRP20250471TT
Other languages
English (en)
Croatian (hr)
Inventor
Lynn Macdonald
Andrew J. Murphy
Chunguang GUO
Natasha Levenkova
Naxin Tu
John Mcwhirter
Vera VORONINA
Faith HARRIS
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of HRP20250471T1 publication Critical patent/HRP20250471T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1264—DNA nucleotidylexotransferase (2.7.7.31), i.e. terminal nucleotidyl transferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07031—DNA nucleotidylexotransferase (2.7.7.31), i.e. terminal deoxynucleotidyl transferase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Environmental Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Peptides Or Proteins (AREA)
HRP20250471TT 2016-06-03 2017-06-02 Glodavci koji eksprimiraju egzogenu terminalnu dezoksinukleotidil transferazu HRP20250471T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662345524P 2016-06-03 2016-06-03
EP23151094.2A EP4218408B1 (en) 2016-06-03 2017-06-02 Rodents expressing exogenous terminal deoxynucleotidyltransferase

Publications (1)

Publication Number Publication Date
HRP20250471T1 true HRP20250471T1 (hr) 2025-06-06

Family

ID=59215996

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20230497TT HRP20230497T1 (hr) 2016-06-03 2017-06-02 Glodavci koji izražavaju egzogenu terminalnu dezoksinukleotidil transferazu
HRP20250471TT HRP20250471T1 (hr) 2016-06-03 2017-06-02 Glodavci koji eksprimiraju egzogenu terminalnu dezoksinukleotidil transferazu

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20230497TT HRP20230497T1 (hr) 2016-06-03 2017-06-02 Glodavci koji izražavaju egzogenu terminalnu dezoksinukleotidil transferazu

Country Status (25)

Country Link
US (2) US10980221B2 (enExample)
EP (3) EP4567104A3 (enExample)
JP (4) JP7053499B2 (enExample)
KR (3) KR102598120B1 (enExample)
CN (3) CN109640644B (enExample)
AU (2) AU2017272337C1 (enExample)
BR (1) BR112018074794A2 (enExample)
CA (1) CA3026088A1 (enExample)
CY (1) CY1126063T1 (enExample)
DK (2) DK3462853T3 (enExample)
ES (2) ES3018427T3 (enExample)
FI (2) FI3462853T3 (enExample)
HR (2) HRP20230497T1 (enExample)
HU (2) HUE071052T2 (enExample)
IL (2) IL263160B2 (enExample)
LT (2) LT3462853T (enExample)
MX (3) MX385681B (enExample)
PL (2) PL4218408T3 (enExample)
PT (2) PT3462853T (enExample)
RS (2) RS64216B1 (enExample)
RU (1) RU2753585C2 (enExample)
SG (2) SG10201914014XA (enExample)
SI (2) SI3462853T1 (enExample)
SM (2) SMT202500152T1 (enExample)
WO (1) WO2017210586A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2958937B1 (en) 2013-02-22 2018-08-15 Regeneron Pharmaceuticals, Inc. Mice expressing humanized major histocompatibility complex
CN109640644B (zh) 2016-06-03 2021-10-26 瑞泽恩制药公司 表达外源末端脱氧核苷酸转移酶的非人动物
SG11202003044SA (en) 2017-12-05 2020-04-29 Regeneron Pharma Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof
US20210051929A1 (en) 2018-03-24 2021-02-25 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
EP3807310A4 (en) * 2018-06-13 2022-03-23 The Children's Medical Center Corporation METHODS AND COMPOSITIONS FOR HIGH-THROUGHPUT MODELS FOR ANTIBODY DISCOVERY AND/OR OPTIMIZATION
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
US11464217B2 (en) * 2019-02-22 2022-10-11 Regeneron Pharmaceuticals, Inc. Rodents having genetically modified sodium channels and methods of use thereof
SG11202111258TA (en) 2019-06-05 2021-11-29 Regeneron Pharma Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof
KR20220114026A (ko) * 2019-12-12 2022-08-17 디엔에이 스크립트 폴리뉴클레오타이드의 주형-부재 효소 합성을 위한 키메라 말단 데옥시뉴클레오타이드 전달효소
CN111057754B (zh) * 2019-12-27 2021-01-12 四川省医学科学院.四川省人民医院实验动物研究所 鉴定适用于hbv研究的动物模型的方法和应用
WO2021154791A1 (en) 2020-01-28 2021-08-05 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized pnpla3 locus and methods of use
AU2021261267A1 (en) * 2020-04-21 2022-09-08 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized Cxcl13 gene
TW202229328A (zh) 2020-09-11 2022-08-01 美商再生元醫藥公司 抗原特異性抗體之鑑定及產生
JP2024500399A (ja) 2020-12-16 2024-01-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化Ｆｃアルファ受容体を発現するマウス
IL303868A (en) 2020-12-23 2023-08-01 Regeneron Pharma Nucleic acids encoding anchor-modified antibodies and uses thereof
CN118511853A (zh) 2021-03-31 2024-08-20 瑞泽恩制药公司 包含具有改善的tcrb组库多样性的人源化细胞免疫系统组分的基因修饰的小鼠
AU2023347224A1 (en) * 2022-09-22 2025-03-20 Regeneron Pharmaceuticals, Inc. Genetically modified mice expressing components of human cellular immune system
WO2025250011A1 (en) 2024-05-29 2025-12-04 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Treatment for cancer

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9119338D0 (en) 1991-09-10 1991-10-23 Inst Of Animal Physiology And Control of gene expression
US5523226A (en) * 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
US5512295A (en) 1994-11-10 1996-04-30 The Board Of Trustees Of The Leland Stanford Junior University Synthetic liposomes for enhanced uptake and delivery
US6001349A (en) 1995-02-22 1999-12-14 Therion Biologics Corporation Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6770291B2 (en) 1996-08-30 2004-08-03 The United States Of America As Represented By The Department Of Health And Human Services Liposome complexes for increased systemic delivery
US7001614B2 (en) 1996-08-19 2006-02-21 The United States Of America As Represented By The Department Of Health And Human Services Liposome complexes for increased systemic delivery
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US7112338B2 (en) 1997-03-12 2006-09-26 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6749863B1 (en) 1997-11-19 2004-06-15 Georgetown University Targeted liposome gene delivery
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP2294917A1 (en) 2001-03-22 2011-03-16 Abbott GmbH & Co. KG Transgenic animals expressing antibodies specific for genes of interest and uses thereof
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8093357B2 (en) 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20090042291A1 (en) 2002-03-01 2009-02-12 Xencor, Inc. Optimized Fc variants
CA2510309C (en) 2002-12-16 2014-09-16 Liyange P. Perera Recombinant vaccine viruses expressing il-15 and methods of using the same
WO2004067753A2 (en) 2003-01-28 2004-08-12 Cellectis Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof.
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
US8218805B2 (en) 2003-10-11 2012-07-10 Charles Hornback Wireless speaker system for use with ceiling fans
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
CA2567814C (en) 2004-05-27 2013-07-23 Jon A. Weidanz Antibodies as t cell receptor mimics, methods of production and uses thereof
PL2767161T3 (pl) 2004-10-19 2018-09-28 Regeneron Pharmaceuticals, Inc. Sposób wytwarzania zwierzęcia homozygotycznego pod względem modyfikacji genetycznej
CA2587766A1 (en) 2004-11-10 2007-03-01 Macrogenics, Inc. Engineering fc antibody regions to confer effector function
US20060222653A1 (en) 2004-11-12 2006-10-05 Xencor, Inc. Antibodies operably linked to selected chemoattractants
EP1858925A2 (en) 2005-01-12 2007-11-28 Xencor, Inc. Antibodies and fc fusion proteins with altered immunogenicity
CN101263158B (zh) * 2005-08-03 2011-12-28 人类多克隆治疗股份有限公司 表达人源化免疫球蛋白的转基因动物中b细胞凋亡的抑制
JP2009504787A (ja) 2005-08-19 2009-02-05 シーラス コーポレイション 抗体によって媒介される免疫応答の増強
ES2937245T3 (es) 2005-08-23 2023-03-27 Univ Pennsylvania ARN que contiene nucleósidos modificados y métodos de uso del mismo
WO2007117410A2 (en) 2006-03-31 2007-10-18 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
SG182144A1 (en) 2007-06-01 2012-07-30 Omt Inc Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
ES2608604T3 (es) 2007-10-18 2017-04-12 Bavarian Nordic A/S Uso de MVA para tratar el cáncer de próstata
US8225343B2 (en) 2008-01-11 2012-07-17 Sony Computer Entertainment America Llc Gesture cataloging and recognition
ES2445193T3 (es) * 2008-06-27 2014-02-28 Merus B.V. Mamíferos no humanos productores de anticuerpos
WO2010039900A2 (en) 2008-09-30 2010-04-08 Aliva Biopharmaceuticals, Inc. Non-human mammals for the production of chimeric antibodies
US8691502B2 (en) 2008-10-31 2014-04-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
ES2948572T3 (es) 2009-07-08 2023-09-14 Kymab Ltd Modelos de roedores y moléculas terapéuticas
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
MY172472A (en) * 2009-12-10 2019-11-26 Regeneron Pharma Mice that make heavy chain antibodies
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US20130185821A1 (en) 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
ES2547142T5 (es) 2010-02-08 2021-12-09 Regeneron Pharma Cadena ligera común de ratón
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) * 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
JP2013523098A (ja) 2010-03-29 2013-06-17 ザイムワークス，インコーポレイテッド 強化又は抑制されたエフェクター機能を有する抗体
KR20210010942A (ko) 2010-03-31 2021-01-28 아블렉시스, 엘엘씨 키메라 항체의 제조를 위한 비-인간 동물의 유전적 조작
MY195217A (en) 2010-06-22 2023-01-11 Regeneron Pharma MICE Expressing An Immunoglobulin Hybrid Light Chain
EP2597945B1 (en) 2010-07-26 2020-07-22 Trianni, Inc. Transgenic animals and methods of use
IL315833A (en) 2010-08-02 2024-11-01 Regeneron Pharma Mice producing binding proteins containing VL regions
HUE024534T2 (hu) 2011-02-25 2016-01-28 Regeneron Pharma ADAM6 egerek
JP5893258B2 (ja) 2011-03-31 2016-03-23 フェリカネットワークス株式会社 情報処理装置および方法、並びにプログラム
US20130018582A1 (en) 2011-07-13 2013-01-17 Miller Paul A Inertial Navigation Common Azimuth Reference Determination System and Method
IL273982B2 (en) 2011-08-05 2023-03-01 Regeneron Pharma Humanized mice possess a universal light chain
EP2757875B2 (en) * 2011-09-19 2023-03-22 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
US10246509B2 (en) 2011-10-17 2019-04-02 Regeneron Pharmaceuticals, Inc. Restricted immunoglobulin heavy chain mice
KR101926442B1 (ko) 2011-10-28 2018-12-12 리제너론 파아마슈티컬스, 인크. 키메라 주요 조직적합성 복합체 （ｍｈｃ） ｉｉ 분자들을 발현하는 유전자 변형된 마우스
PL2663575T3 (pl) 2011-10-28 2015-03-31 Regeneron Pharma Humanizowane IL-6 i receptor IL-6
SMT202100243T1 (it) 2011-10-28 2021-05-07 Regeneron Pharma Topi con recettori delle cellule t geneticamente modificati
DK2770821T3 (da) 2011-10-28 2017-11-27 Regeneron Pharma Genetisk modificerede major histocompatibility-kompleks-mus
US9043996B2 (en) 2011-10-28 2015-06-02 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
US9591835B2 (en) 2011-10-28 2017-03-14 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
EP2773671B1 (en) 2011-11-04 2021-09-15 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
US9120662B2 (en) 2011-11-14 2015-09-01 Susan A. Thomson Gathering and dispensing scoop with gate valve
US9547499B2 (en) 2011-12-09 2017-01-17 Microsoft Technology Licensing, Llc Device configuration with cached pre-assembled driver state
EP2825036B1 (en) 2012-03-16 2018-05-02 Regeneron Pharmaceuticals, Inc. Histidine engineered light chain antibodies and genetically modified rodents for generating the same
RU2664473C2 (ru) 2012-03-16 2018-08-17 Регенерон Фармасьютикалз, Инк. ОТЛИЧНЫЕ ОТ ЧЕЛОВЕКА ЖИВОТНЫЕ, ЭКСПРЕССИРУЮЩИЕ ЧУВСТВИТЕЛЬНЫЕ К pН ПОСЛЕДОВАТЕЛЬНОСТИ ИММУНОГЛОБУЛИНОВ
AU2013204581B2 (en) 2012-03-16 2015-06-25 Regeneron Pharmaceuticals, Inc. Non-human animals expressing pH-sensitive immunoglobulin sequences
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
JP5920830B2 (ja) 2012-09-28 2016-05-18 シスメックス株式会社 試料調製装置および細胞分析装置
PL3653049T3 (pl) 2012-12-14 2024-02-26 Omniab, Inc. Polinukleotydy kodujące przeciwciała gryzoni z ludzkimi idiotypami i zwierzęta je zawierające
SMT201800435T1 (it) 2013-02-20 2018-09-13 Regeneron Pharma Animali non umani con sequenze della catena pesante dell’immunoglobulina modificate riferimento incrociato a domande correlate
LT2958938T (lt) 2013-02-20 2019-07-25 Regeneron Pharmaceuticals, Inc. Pelės, ekspresuojančios humanizuotus t ląstelių koreceptorius
EP2958937B1 (en) 2013-02-22 2018-08-15 Regeneron Pharmaceuticals, Inc. Mice expressing humanized major histocompatibility complex
SG10201808935WA (en) 2013-04-16 2018-11-29 Regeneron Pharma Targeted modification of rat genome
US9783618B2 (en) * 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
JP6174811B2 (ja) 2013-12-11 2017-08-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ゲノムの標的改変のための方法及び組成物
BR112016021572A2 (pt) 2014-03-21 2017-10-03 Regeneron Pharma Métodos para preparar um animal não humano geneticamente modificado e para produzir proteínas de ligação, hibridoma, ácido nucleico, célula, e, proteína de ligação
ES2762640T3 (es) 2014-03-21 2020-05-25 Regeneron Pharma Proteínas VL de unión a antígeno que exhiben diferentes características de unión
MX385689B (es) 2014-06-06 2025-03-18 Regeneron Pharma Métodos y composiciones para modificar un locus dirigido.
CN106604635B (zh) * 2014-06-19 2020-01-14 瑞泽恩制药公司 具有人源化程序性细胞死亡1基因的非人动物
US9738897B2 (en) 2014-06-23 2017-08-22 Regeneron Pharmaceuticals, Inc. Nuclease-mediated DNA assembly
WO2015200805A2 (en) 2014-06-26 2015-12-30 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modifications and methods of use
RU2017113134A (ru) 2014-09-19 2018-10-19 Регенерон Фармасьютикалз, Инк. Химерные антигенные рецепторы
KR20240132525A (ko) 2015-04-06 2024-09-03 리제너론 파아마슈티컬스, 인크. 비인간 동물에서의 인간화 t 세포 매개 면역반응
CN109640644B (zh) 2016-06-03 2021-10-26 瑞泽恩制药公司 表达外源末端脱氧核苷酸转移酶的非人动物

Also Published As

Publication number Publication date
RU2753585C2 (ru) 2021-08-18
KR20230156162A (ko) 2023-11-13
SMT202500152T1 (it) 2025-05-12
CN109640644B (zh) 2021-10-26
ES2941810T3 (es) 2023-05-25
FI4218408T3 (fi) 2025-04-25
HUE061619T2 (hu) 2023-07-28
PL4218408T3 (pl) 2025-06-09
SMT202300132T1 (it) 2023-05-12
CN116458475A (zh) 2023-07-21
NZ749707A (en) 2024-04-26
RU2018144954A3 (enExample) 2020-10-02
EP4218408B1 (en) 2025-03-19
CN109640644A (zh) 2019-04-16
US20210195877A1 (en) 2021-07-01
EP4567104A2 (en) 2025-06-11
US20170347633A1 (en) 2017-12-07
JP2019521668A (ja) 2019-08-08
KR102784608B1 (ko) 2025-03-27
IL263160B2 (en) 2024-01-01
JP7586960B2 (ja) 2024-11-19
PT4218408T (pt) 2025-03-26
ES3018427T3 (es) 2025-05-16
DK3462853T3 (da) 2023-04-03
RU2018144954A (ru) 2020-07-14
CA3026088A1 (en) 2017-12-07
MX385681B (es) 2025-03-18
RS64216B1 (sr) 2023-06-30
AU2017272337A8 (en) 2019-03-14
US10980221B2 (en) 2021-04-20
KR102598120B1 (ko) 2023-11-07
AU2017272337C1 (en) 2024-02-29
AU2017272337B9 (en) 2023-12-14
JP7053499B2 (ja) 2022-04-12
KR20190031447A (ko) 2019-03-26
HUE071052T2 (hu) 2025-07-28
JP7274018B2 (ja) 2023-05-15
IL304839A (en) 2023-09-01
BR112018074794A2 (pt) 2019-03-12
PL3462853T3 (pl) 2023-06-26
WO2017210586A1 (en) 2017-12-07
MX2021010351A (es) 2021-10-13
AU2024200577A1 (en) 2024-02-22
CY1126063T1 (el) 2023-11-15
KR20230006053A (ko) 2023-01-10
WO2017210586A8 (en) 2018-05-03
MX2021010352A (es) 2021-10-22
CN113907043B (zh) 2023-08-01
HRP20230497T1 (hr) 2023-07-21
LT4218408T (lt) 2025-05-12
JP2023093729A (ja) 2023-07-04
EP3462853A1 (en) 2019-04-10
US12295354B2 (en) 2025-05-13
IL263160B1 (en) 2023-09-01
MX2018014982A (es) 2019-09-18
EP4218408A1 (en) 2023-08-02
JP2022088597A (ja) 2022-06-14
SG10201914014XA (en) 2020-03-30
JP2025020339A (ja) 2025-02-12
KR102483193B1 (ko) 2023-01-04
SI3462853T1 (sl) 2023-05-31
EP3462853B1 (en) 2023-03-01
SG11201810757YA (en) 2018-12-28
AU2017272337B2 (en) 2023-11-09
CN113907043A (zh) 2022-01-11
EP4567104A3 (en) 2025-09-24
RS66700B1 (sr) 2025-05-30
LT3462853T (lt) 2023-03-27
FI3462853T3 (fi) 2023-04-05
SI4218408T1 (sl) 2025-06-30
DK4218408T3 (da) 2025-04-14
IL263160A (en) 2018-12-31
PT3462853T (pt) 2023-04-21
AU2017272337A1 (en) 2019-01-24

Similar Documents

Publication Publication Date Title
HRP20250471T1 (hr) Glodavci koji eksprimiraju egzogenu terminalnu dezoksinukleotidil transferazu
DK2517557T3 (en) Animal models and therapeutic molecules
US11224207B2 (en) Non-human animals expressing pH-sensitive immunoglobulin sequences
DK2825036T3 (en) Histidine engineered light chain antibodies and genetically modified rodents to generate them
AU2014323527B2 (en) Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
HRP20192311T1 (hr) Adam6 miševi
JP2021505141A5 (enExample)
RU2016141307A (ru) Отличные от человека животные, которые вырабатывают однодоменные связывающие белки
JP2022088597A5 (enExample)
SI2602323T1 (en) Compositions and procedures for inhibiting endogenous immunoglobin gene and the formation of transgenic human idiopathic antibodies
HRP20201403T1 (hr) Neljudske životinje koje imaju genetski modificiran lokus imunoglobulinskog lambda lakog lanca
TR201802443T4 (tr) Bir beşeri değişken bölge ve bir kemirgen sabit bölgesi içeren bir antikor üretmenin bir usulü.
JP2019521668A5 (enExample)
JP2015502149A5 (enExample)
US20150033372A1 (en) Human VpreB & Chimaeric Surrogate Light Chains in Transgenic Non-Human Vertebrates
HRP20200613T1 (hr) Neljudske životinje koje imaju humanizirani gen 1 za programiranu staničnu smrt
JP6775224B2 (ja) マウス人工染色体ベクター及びその使用
Kelsch et al. Genetic labeling of neuronal subsets through enhancer trapping in mice
NZ749707B2 (en) Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
Rosenfeld Animal models of transgenerational epigenetic effects
HK1237588B (en) Animal models and therapeutic molecules
HK40075382A (en) Rodent models and therapeutic antibodies
RU2021131650A (ru) Отличные от человека животные, имеющие ограниченный репертуар легких лямбда-цепей, экспрессируемый из локуса капли, и их применение
Masoumeh et al. Retroviral transduction of fluonanobody and the variable domain of camelid heavy-chain antibodies to chicken embryonic cells
NZ763860B2 (en) Humanized c5 and c3 animals